Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a Healthcare company (Biotechnology) with a market capitalization of $11.2B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Kymera Therapeutics, Inc. had a Maz Rating of 3.04 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.52), among the strongest in its sector; its weakest was Valuation (1.12), among the most expensive in its sector. The other factors: Financial Health 3.60 (above most of its sector); Profitability 2.87 (around the middle of its sector); Growth 1.69 (below most of its sector). The current rating is for members: log in to see it.
At $131.73, Kymera Therapeutics, Inc. trades at 110.0x sales and 8.2x book value. Over the last twelve months it generated about $102M of revenue and a net loss of $310M. It runs an operating margin of -396.1% and a net margin of -341.9%. It shows return on equity of -22.4%, return on invested capital of -23.9% and a free cash flow yield of -2.6%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 11.13. Over the past 52 weeks the share price ranged from $58.87 to $138.00, with a beta of 2.03.
Kymera Therapeutics, Inc. does not currently pay a dividend.
27 Wall Street analyst ratings cover the stock: 24 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.